Clinical Trial Update: Study of CYR-101 in Patients With Schizophrenia [Phase 2]

View source ↗

Summary

CYR-101, developed by Cyrenaic Pharmaceuticals, completed a Phase 2 trial in schizophrenia. This update provides the trial status of the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• CYR-101

Snippet

Sponsor: Cyrenaic Pharmaceuticals | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED